Implementing Shared-Decision Making Strategies: Screening, Diagnosis, and Treatment
of Major Depressive Disorder

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 15, 2018 to August 15, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Takeda Pharmaceuticals USA and Lundbeck

Major depression is a debilitating condition that nearly 20% of the general population in the United States will experience at some point in their life. With appropriate treatment, 70-80% of individuals with major depressive disorder (MDD) can achieve a significant reduction in symptoms. More than 80% of patients with depression have a medical comorbidity or complications that can come from MDD to include alcohol or substance abuse, type 2 diabetes, dyslipidemia, obesity, cardiovascular disease, isolation, work and personal conflicts, and an increased chance of suicide. A diagnosis of clinical depression requires the presence of depressed mood, a loss of pleasure and interest, decreased energy, changes in sleep patterns, and feelings of worthlessness, hopelessness, or guilt for a period of at least 2 weeks. The disease leaves the patient with significant distress and impairs their ability to function. Measurement-based assessment tools can help quantify the degree of depression and it is important to utilize a focused severity assessment for hopelessness, suicidal ideation, and psychotic symptoms since these factors independently increase the risk for suicide.

Treatment may be multi-faceted, combining medication with psychotherapy however treatment may change several times as different medications affect people in different ways. Treatments for MDD range from psychotherapy, antidepressants, electroconvulsive treatment (ECT), and other somatic therapies. Antidepressant treatments include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), atypical and tricyclic antidepressants, monoamine oxidase inhibitors and other medications. Combination can affect multiple monoamine targets which can produce greater efficacy. While there are many options available, the need to personalize a treatment plan for each individual patient is important as the ultimate goal of care is to move patients suffering from MDD to remission, then recovery, and to avoid a relapse.

Upon completion of this activity, participants will be able to:

  • Evaluate the efficacy, tolerability, and practical considerations of pharmacologic therapies for major depressive disorder (MDD).

  • Explore the importance of including measurement tools in diagnosing the severity of MDD.

  • Assess strategies for patients in shared decision-making to optimize their treatment options to manage all symptoms of MDD.

  • Discuss the best practices of assessing, monitoring, and maintaining patient adherence with pharmacologic therapy for MDD.

Faculty: Michael E. Thase, MD
Professor, Department of Psychiatry
Perelman School of Medicine
University of Pennsylvania


Dr. Thase serves on an advisory board for Acadia, Alkermes, Allergan, AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer Pharmaceuticals, Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Inc., Merck, Moksha8, Nestlé (PamLab), Neuralstem, Novartis, Otsuka, Pfizer, Shire, Sunovion and Takeda. He has received research/grant support from Acadia, Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Axome, Forest Pharmaceuticals, Intracellular, Janssen, National Institute of Mental Health, Otsuka Pharmaceuticals, PCORI and Takeda. He owns stock in MedAvante, Inc. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Takeda Pharmaceuticals USA and Lundbeck

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue